



Transgene Announces Participation at Upcoming Investor Events

Strasbourg, France, March 2nd, 2016 – Transgene today announced that management will participate in the upcoming events outlined below.

SFAF Meeting: Transgene will present its annual 2015 results on March 9, 2016 at 11:30am. The meeting is being held at the Centre de Conference Etoile Honoré in Paris. A conference call and webcast in English will be held on the same day at 2:30pm.

Cowen and Company 36th Annual Health Care Conference: The conference is being held in Boston, MA, March 7-9, 2016. Transgene will give a corporate presentation on March 9 at 8:00am. The presentation will be webcast.

9th Kempen Life Sciences Conference: Transgene will meet with institutional investors on April 7, 2016 in Amsterdam, The Netherlands.

About Transgene

Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company's two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.

Contacts:

Transgene

Elisabetta Castelli, Director IR
+33 (0)3 88 27 91 21
investorrelations@transgene.fr

MC Services

Raimund Gabriel
+49 89 210 228 30
raimund.gabriel@mc-services.eu

Shaun Brown
+44 207 148 5998
shaun.brown@mc-services.eu